AbbVie Reports SKYRIZI and RINVOQ Data in Inflammatory Bowel Disease
AbbVie shared new data for SKYRIZI and RINVOQ indicating disease control in patients with inflammatory bowel disease. The Phase 3 AFFIRM trial found subcutaneous SKYRIZI yielded significantly better clinical remission and endoscopic response than placebo at week 12, and the rates were numerically higher through week 24 for clinical responders. Long-term extension results showed sustained outcomes for SKYRIZI up to 144 weeks, while real-world RINVOQ data showed remission in many hard-to-treat Crohn's disease patients.
AbbVie presented results from several studies of SKYRIZI and RINVOQ in inflammatory bowel disease. In the Phase 3 AFFIRM trial, subcutaneous SKYRIZI outperformed placebo for clinical remission and endoscopic response at week 12, with numerical advantages maintained at week 24 among clinical responders.
Longer-term extension data indicated durable SKYRIZI results through 144 weeks in FORTIFY, 148 weeks in SEQUENCE, and three years in COMMAND. FORTIFY also found that 74.5% of patients with fistulizing Crohn's disease had no draining fistulas after five years. Real-world RINVOQ data reported remission in many difficult-to-treat Crohn's patients, including six-month rates of 57% clinical remission, 58% endoscopic response, and 53.6% endoscopic remission.
If the results hold in practice, people with difficult-to-treat Crohn's disease or ulcerative colitis could see more chances of symptom control and less corticosteroid reliance. Clinicians may gain more evidence when choosing among advanced therapies. Health systems and payers could face questions about access, cost, and long-term use, while caregivers may benefit from reduced disease burden. Still, real-world impact depends on regulatory review, coverage, and individual patient factors.